ProCE Banner Activity

What Is the Role for Antidepressants in Bipolar Disorder?

Podcast Episodes
Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder.

Released: October 05, 2021

Expiration: October 04, 2022

No longer available for credit.

Share

Faculty

Joseph F. Goldberg

Joseph F. Goldberg, MD

Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
President
St. Charles Psychiatry Associates
St. Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Intra Cellular Therapies

Faculty Disclosure

Primary Author

Joseph F. Goldberg, MD

Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Joseph Goldberg, MD, has disclosed that he has received consulting fees from BioXcel, Lundbeck, Otsuka, and Sunovion and fees for non-CME/CE services from Allergan, Intercellular Therapies, and Sunovion.

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
President
St. Charles Psychiatry Associates
St. Louis, Missouri

Greg Mattingly, MD, has disclosed that he has received consulting fees from AbbVie, Acadia, Alkermes, Axsome, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Otsuka, Redax, Roche, Rhodes, Sage, Shire, Sunovion, Supernus, Takeda, Teva, and Trispharma; funds for research support from AbbVie, Acadia, Alkermes, Avanir, Axsome, Boehringer Ingelheim, Emalex, Janssen, Medgenics, NLS-1 Pharma AG, Redax, Roche, Sage, Shire, Sunovion, Supernus, Takeda, and Teva; and fees for non-CME/CE services from AbbVie, Alkermes, Eisai, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, and Trispharma.